Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Dec 15

PMID 26655300

Citations 36

Authors

Kentaro Yamada

Kazuko Noguchi

Takashi Komeno

Yousuke Furuta

Akira Nishizono

Affiliations

Soon will be listed here.

Abstract

Rabies is a fatal encephalitis caused by rabies virus (RABV), and no antiviral drugs for RABV are currently available. We report for the first time the efficacy of favipiravir (T-705) against RABV in vitro and in vivo. T-705 produced a significant, 3-4 log10 reduction in the multiplication of street and fixed RABV strains in mouse neuroblastoma Neuro-2a cells, with half-maximal inhibitory concentrations of 32.4 µM and 44.3 µM, respectively. T-705 significantly improved morbidity and mortality among RABV-infected mice when orally administered at a dose of 300 mg/kg/day for 7 days, beginning 1 hour after inoculation. T-705 significantly reduced the rate of virus positivity in the brain. Furthermore, the effectiveness of T-705 was comparable to that of equine rabies virus immunoglobulin for postexposure prophylaxis. Collectively, our results suggest that T-705 is active against RABV and may serve as a potential alternative to rabies immunoglobulin in rabies postexposure prophylaxis.

Citing Articles

Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in .

Shiraki K, Mishima M, Sato N, Imoto Y, Nishiwaki K Heliyon. 2024; 10(15):e35331.

PMID: 39165990 PMC: 11334893. DOI: 10.1016/j.heliyon.2024.e35331.

Puppies as the primary causal animal for human rabies cases: three-year prospective study of human rabies in the Philippines.

Saito N, Inton K, Mauhay J, Solante R, Guzman F, Yamada K Front Microbiol. 2024; 15:1425766.

PMID: 39040907 PMC: 11260713. DOI: 10.3389/fmicb.2024.1425766.

A Robust Phenotypic High-Throughput Antiviral Assay for the Discovery of Rabies Virus Inhibitors.

Wang X, Chiu W, Klaassen H, Marchand A, Chaltin P, Neyts J Viruses. 2023; 15(12).

PMID: 38140533 PMC: 10747594. DOI: 10.3390/v15122292.

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro.

Chi Y, Xie Y, Liu S, Zhu W Virol J. 2023; 20(1):258.

PMID: 37950261 PMC: 10638713. DOI: 10.1186/s12985-023-02213-w.

Deoxynivalenol Mycotoxin Inhibits Rabies Virus Replication In Vitro.

Liu Q, He Q, Zhu W Int J Mol Sci. 2023; 24(9).

PMID: 37175500 PMC: 10178062. DOI: 10.3390/ijms24097793.

References

Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K . In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46(4):977-81. PMC: 127093. DOI: 10.1128/AAC.46.4.977-981.2002. View

Hirai K, Kawano H, Mifune K, Fujii H, Nishizono A, Shichijo A . Suppression of cell-mediated immunity by street rabies virus infection. Microbiol Immunol. 1992; 36(12):1277-90. DOI: 10.1111/j.1348-0421.1992.tb02130.x. View

Willoughby Jr R, Tieves K, Hoffman G, Ghanayem N, Amlie-Lefond C, Schwabe M . Survival after treatment of rabies with induction of coma. N Engl J Med. 2005; 352(24):2508-14. DOI: 10.1056/NEJMoa050382. View

Dodet B . Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine. 2006; 24(16):3045-9. DOI: 10.1016/j.vaccine.2005.10.015. View

Morrey J, Taro B, Siddharthan V, Wang H, Smee D, Christensen A . Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 2008; 80(3):377-9. PMC: 2587511. DOI: 10.1016/j.antiviral.2008.07.009. View

Bakker A, Python C, Kissling C, Pandya P, Marissen W, Brink M . First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine. 2008; 26(47):5922-7. DOI: 10.1016/j.vaccine.2008.08.050. View

Bourhy H, Goudal M, Mailles A, Sadkowska-Todys M, Dacheux L, Zeller H . Is there a need for anti-rabies vaccine and immunoglobulins rationing in Europe?. Euro Surveill. 2009; 14(13). View

Julander J, Smee D, Morrey J, Furuta Y . Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res. 2009; 82(3):169-71. PMC: 2704019. DOI: 10.1016/j.antiviral.2009.02.201. View

Shiota S, Mannen K, Matsumoto T, Yamada K, Yasui T, Takayama K . Development and evaluation of a rapid neutralizing antibody test for rabies. J Virol Methods. 2009; 161(1):58-62. DOI: 10.1016/j.jviromet.2009.05.018. View

10.

Fang L, Ping F, Ping D, Hui B, Yan Y . Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. Vaccine. 2010; 28(42):6847-51. DOI: 10.1016/j.vaccine.2010.08.034. View

11.

Hossain M, Bulbul T, Ahmed K, Ahmed Z, Salimuzzaman M, Haque M . Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh. Vaccine. 2010; 29(5):1036-40. DOI: 10.1016/j.vaccine.2010.11.052. View

12.

Yamada K, Park C, Noguchi K, Kojima D, Kubo T, Komiya N . Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus. Virus Res. 2012; 165(1):34-45. DOI: 10.1016/j.virusres.2012.01.002. View

13.

Both L, Banyard A, van Dolleweerd C, Horton D, Ma J, Fooks A . Passive immunity in the prevention of rabies. Lancet Infect Dis. 2012; 12(5):397-407. DOI: 10.1016/S1473-3099(11)70340-1. View

14.

Gogtay N, Thatte U, Kshirsagar N, Leav B, Molrine D, Cheslock P . Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012; 30(50):7315-20. DOI: 10.1016/j.vaccine.2012.09.027. View

15.

Jackson A . Current and future approaches to the therapy of human rabies. Antiviral Res. 2013; 99(1):61-7. DOI: 10.1016/j.antiviral.2013.01.003. View

16.

Naesens L, Guddat L, Keough D, van Kuilenburg A, Meijer J, Vande Voorde J . Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 2013; 84(4):615-29. DOI: 10.1124/mol.113.087247. View

17.

Yamada K, Noguchi K, Nishizono A . Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein. Arch Virol. 2013; 159(2):207-16. DOI: 10.1007/s00705-013-1805-5. View

18.

Yamaoka S, Ito N, Ohka S, Kaneda S, Nakamura H, Agari T . Involvement of the rabies virus phosphoprotein gene in neuroinvasiveness. J Virol. 2013; 87(22):12327-38. PMC: 3807887. DOI: 10.1128/JVI.02132-13. View

19.

. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser. 2013; (982):1-139, back cover. View

20.

Furuta Y, Gowen B, Takahashi K, Shiraki K, Smee D, Barnard D . Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100(2):446-54. PMC: 3880838. DOI: 10.1016/j.antiviral.2013.09.015. View